Sleep Number's Q3 Losses Widen Amid Sales Slump, Restructuring Costs

Ticker: SNBR · Form: 10-Q · Filed: 2025-11-05T00:00:00.000Z

Sentiment: bearish

Topics: Retail, Mattress Industry, Financial Performance, Restructuring, Debt Covenants, Net Loss, Sales Decline

Related Tickers: SNBR, TPX, PRPL

TL;DR

**SNBR is bleeding cash and restructuring, avoid this stock until they show a clear path to profitability.**

AI Summary

Sleep Number Corp (SNBR) reported a significant decline in financial performance for the three and nine months ended September 27, 2025. Net sales decreased by 19.6% to $342.88 million for the three months ended September 27, 2025, compared to $426.62 million in the prior year period. The company posted a net loss of $39.79 million for the quarter, a substantial increase from a net loss of $3.14 million in the same period last year. For the nine months, net sales fell to $1.06 billion from $1.31 billion, and the net loss widened to $73.45 million from $15.67 million. Key business changes include a $16.1 million impairment charge related to ending operations with a strategic product-development partner, and restructuring costs surged to $39.15 million for the quarter, up from $1.96 million. The company also amended its credit facility on November 4, 2025, extending the maturity date to December 3, 2027, but reducing the revolving credit facility and increasing interest rates and amortization payments, while adjusting financial covenants like the Net Leverage Ratio and Interest Coverage Ratio. Cash and cash equivalents decreased to $1.26 million as of September 27, 2025, from $1.95 million at December 28, 2024.

Why It Matters

Sleep Number's deepening losses and declining sales signal significant operational challenges, impacting investor confidence and potentially leading to further stock price volatility. The substantial increase in restructuring costs and the impairment charge indicate a strategic pivot, which could affect employees through layoffs and customers through potential product line changes. The amended credit facility, with its reduced capacity and stricter covenants, highlights the company's precarious financial position, potentially limiting future growth investments and increasing borrowing costs. In a competitive mattress market, these financial strains could weaken Sleep Number's ability to innovate and compete effectively against rivals like Tempur Sealy and Purple Innovation.

Risk Assessment

Risk Level: high — The company reported a net loss of $39.79 million for the three months ended September 27, 2025, a significant increase from $3.14 million in the prior year. Total liabilities exceed total assets, resulting in a shareholders' deficit of $521.34 million, indicating severe financial distress. Furthermore, the credit facility amendment includes increased interest rates (e.g., 4.0% for Term SOFR Loans until December 31, 2026) and more stringent financial covenants, such as a maximum Net Leverage Ratio of 5.25 to 1.00 for the quarter ended September 27, 2025, and a minimum Liquidity of $30 million, suggesting tight financial controls and limited flexibility.

Analyst Insight

Investors should exercise extreme caution and consider divesting from Sleep Number (SNBR) given the widening losses, declining sales, and increased financial leverage. Monitor the company's ability to meet the new, stricter credit facility covenants and any further restructuring announcements, as these will be critical indicators of its long-term viability.

Financial Highlights

revenue
$342.88M
total Assets
$749.39M
total Debt
$1.27B
net Income
$(39.79M)
gross Margin
59.89%
cash Position
$1.26M
revenue Growth
-19.6%

Key Numbers

Key Players & Entities

FAQ

What were Sleep Number's net sales for the third quarter of 2025?

Sleep Number's net sales for the three months ended September 27, 2025, were $342.88 million, a decrease from $426.62 million in the same period of 2024.

How much was Sleep Number's net loss in Q3 2025?

Sleep Number reported a net loss of $39.79 million for the three months ended September 27, 2025, significantly higher than the $3.14 million net loss in Q3 2024.

What were the restructuring costs for Sleep Number in the third quarter of 2025?

Restructuring costs for Sleep Number in the third quarter of 2025 amounted to $39.15 million, a substantial increase from $1.96 million in the prior year's third quarter.

Did Sleep Number incur any impairment charges in Q3 2025?

Yes, Sleep Number recorded an impairment charge of $16.13 million in the third quarter of 2025, related to ending business operations with a strategic product-development partner.

What is Sleep Number's current shareholders' deficit?

As of September 27, 2025, Sleep Number's total shareholders' deficit was $521.34 million, worsening from $451.59 million at December 28, 2024.

What changes were made to Sleep Number's credit facility?

On November 4, 2025, Sleep Number amended its credit facility, extending the maturity to December 3, 2027, reducing the revolving credit facility from $485 million to $475 million, and adjusting financial covenants and interest rates.

What is the new maximum Net Leverage Ratio for Sleep Number?

The amended credit agreement adjusts the permissible maximum Net Leverage Ratio to 5.25 to 1.00 for the quarterly reporting period ended September 27, 2025, with further adjustments for subsequent periods.

How has Sleep Number's cash position changed?

Cash and cash equivalents decreased to $1.26 million as of September 27, 2025, from $1.95 million at December 28, 2024, reflecting a net decrease of $686 thousand.

What is the impact of the new FASB ASU 2024-03 on Sleep Number?

ASU 2024-03 requires more detailed expense disclosures, effective for Sleep Number beginning with the 2027 annual period. The company is currently evaluating its impact on consolidated financial statements.

What should investors consider regarding Sleep Number's future outlook?

Investors should consider the company's ability to manage its increased debt burden, meet stricter financial covenants, and reverse the trend of declining sales and widening losses, especially given the competitive market and ongoing restructuring efforts.

Risk Factors

Industry Context

The bedding and mattress industry is highly competitive, with companies like Sleep Number facing pressure from traditional retailers, direct-to-consumer brands, and private label offerings. Trends include a focus on personalized comfort, sleep technology integration, and direct online sales channels. However, the sector can be sensitive to consumer discretionary spending and economic downturns.

Regulatory Implications

Sleep Number must ensure compliance with the amended credit facility covenants, particularly the Net Leverage Ratio and Interest Coverage Ratio. Failure to meet these could lead to default. Additionally, any future accounting standard changes, like those related to credit losses or expense recognition, require careful evaluation and implementation.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Shareholders' Deficit
Occurs when a company's total liabilities exceed its total assets, resulting in a negative equity position. (Sleep Number's shareholders' deficit has worsened to $(521.34 million), indicating a significant erosion of shareholder value and a precarious financial standing.)
Net Leverage Ratio
A financial metric that measures a company's ability to pay off its debts. It is calculated by dividing total debt by earnings before interest, taxes, depreciation, and amortization (EBITDA). (The amended credit facility imposes a maximum Net Leverage Ratio of 5.25 to 1.00 for Q3 2025, a key covenant the company must now adhere to.)
Impairment Charge
A charge taken when the carrying amount of an asset on the balance sheet is deemed unrecoverable or its fair value has fallen significantly below its book value. (Sleep Number recorded a $16.1 million impairment charge related to a strategic partner, indicating a loss on an investment or asset.)
Restructuring Costs
Expenses incurred by a company when it undergoes significant organizational changes, such as layoffs, facility closures, or business divestitures. (These costs surged to $39.15 million in Q3 2025, significantly impacting profitability and signaling major operational adjustments.)
Term SOFR Loans
Loans that are benchmarked to the Secured Overnight Financing Rate (SOFR), a widely used benchmark interest rate. (The applicable margin for these loans has increased to 4.0% until December 31, 2026, raising the cost of borrowing.)

Year-Over-Year Comparison

Compared to the prior year period, Sleep Number Corp. has experienced a significant deterioration in its financial performance. Net sales for the three months ended September 27, 2025, declined by 19.6% to $342.88 million. The company's profitability has sharply worsened, with a net loss of $39.79 million in Q3 2025, a substantial increase from a $3.14 million loss in Q3 2024. This downturn is exacerbated by a dramatic rise in restructuring costs to $39.15 million from $1.96 million, alongside a $16.1 million impairment charge. Furthermore, the company's liquidity has decreased, with cash and cash equivalents falling to $1.26 million, while its debt obligations have increased, and its shareholders' deficit has widened.

Filing Stats: 4,473 words · 18 min read · ~15 pages · Grade level 15.3 · Accepted 2025-11-05 16:21:33

Key Financial Figures

Filing Documents

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION 1 Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Shareholders' Deficit 3 Condensed Consolidated Statements of Cash Flows 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28

: OTHER INFORMATION

PART II: OTHER INFORMATION 29 Item 1.

Legal Proceedings

Legal Proceedings 29 Item 1A.

Risk Factors

Risk Factors 29 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29 Item 3. Defaults Upon Senior Securities 29 Item 4. Mine Safety Disclosures 29 Item 5. Other Information 29 Item 6. Exhibits 30

SIGNATURES

SIGNATURES 32 1 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION Table of contents

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS SLEEP NUMBER CORPORATION AND SUBSIDIARIES Condensed Consolidated Balance Sheets (unaudited - in thousands, except per share amounts) September 27, 2025 December 28, 2024 Assets Current assets: Cash and cash equivalents $ 1,264 $ 1,950 Accounts receivable, net of allowances of $ 920 and $ 1,113 , respectively 13,902 17,516 Inventories 89,831 103,152 Income taxes receivable 11,903 — Prepaid expenses 14,355 14,568 Other current assets 38,545 44,098 Total current assets 169,800 181,284 Non-current assets: Property and equipment, net 95,126 129,574 Operating lease right-of-use assets 316,959 356,641 Goodwill and intangible assets, net 66,246 66,412 Deferred income taxes 24,930 33,575 Other non-current assets 76,327 93,324 Total assets $ 749,388 $ 860,810 Liabilities and Shareholders' Deficit Current liabilities: Borrowings under credit facility $ 579,500 $ 546,600 Accounts payable 106,967 107,619 Customer prepayments 36,754 46,933 Accrued sales returns 14,932 19,092 Compensation and benefits 18,537 31,038 Taxes and withholding 10,555 18,619 Operating lease liabilities 82,001 82,307 Other current liabilities 49,566 55,804 Total current liabilities 898,812 908,012 Non-current liabilities: Operating lease liabilities 279,028 307,201 Other non-current liabilities 92,890 97,183 Total liabilities 1,270,730 1,312,396 Shareholders' deficit: Undesignated preferred stock; 5,000 shares authorized, no shares issued and outstanding — — Common stock, $ 0.01 par value; 142,500 shares authorized, 22,790 and 22,388 shares issued and outstanding, respectively 228 224 Additional paid-in capital 31,078 27,390 Accumulated deficit ( 552,648 ) ( 479,200 ) Total shareholders' deficit ( 521,342 ) ( 451,586 ) Total liabilities and shareholders' deficit $ 749,388

financial statements more detailed information about the types of expenses included in certain expense captions in the

financial statements more detailed information about the types of expenses included in certain expense captions in the consolidated financial statements, including purchases of inventory, employee compensation, and depreciation and amortization. The amendments are effective for the Company beginning with the 2027 annual period and in interim periods beginning in 2028. Early adoption is permitted. The ASU may be adopted prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements and related disclosures. In July 2025, the FASB issued ASU 2025-05, " Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets " , which provides a practical expedient related to the estimation of 6 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION Table of Contents SLEEP NUMBER CORPORATION AND SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited) expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under Topic 606, including those assets acquired in a business combination. The practical expedient permits an entity to assume that current conditions as of the balance sheet date do not change for the remaining life of the current accounts receivable and current contract assets. This guidance is effective for the Company for its fiscal year and all interim periods beginning January 4, 2026 on a prospective basis. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on its condensed consolidated financial statements. Currently, management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted in their current form, would have a material impact on the Company's consolidated financial statements. Other Investments The Company made a pay

View on Read The Filing